Tissue microarray analysis of cyclin-dependent kinase inhibitors p21 and p16 in fuchs dystrophy

Cornea

Volumn 32, Issue 4, 2013, Pages 473-478

  Matthaei, Mario ^a,b   Lackner, Eva Maria ^a,c   Meng, Huan ^a   Hicks, Jessica L ^d,e   Meeker, Alan K ^d,e   Eberhart, Charles G ^a,d,e   Jun, Albert S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

cyclin dependent kinase inhibitor; Fuchs dystrophy; tissue microarray

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ADULT; AGED; ANTIBODY LABELING; ANTIBODY SPECIFICITY; ARTICLE; CONGENITAL CORNEA DYSTROPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATOCONUS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE; TISSUE MICROARRAY; TISSUE SECTION; VALIDATION PROCESS;

AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; FUCHS' ENDOTHELIAL DYSTROPHY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; TISSUE ARRAY ANALYSIS;

EID: 84875220396     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31826f324e     Document Type: Article

References (30)

1. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol. 2005; 37:961-976.
2. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol. 2007; 8:729-740.
3. Muller M. Cellular senescence: molecular mechanisms, in vivo significance, and redox considerations. Antioxid Redox Signal. 2009; 11:59-98.
4. Jun AS, Meng H, Ramanan N, et al. An alpha 2 collagen VIII transgenic knock-in mouse model of Fuchs endothelial corneal dystrophy shows early endothelial cell unfolded protein response and apoptosis. Hum Mol Genet. 2012; 21:384-393.
5. Engler C, Kelliher C, Spitze AR, et al. Unfolded protein response in Fuchs endothelial corneal dystrophy: a unifying pathogenic pathway? Am J Ophthalmol. 2010; 149:194-202.e2.
6. Wang Z, Handa JT, Green WR, et al. Advanced glycation end products and receptors in Fuchs' dystrophy corneas undergoing Descemet's stripping with endothelial keratoplasty. Ophthalmology. 2007; 114: 1453-1460.
7. Jurkunas UV, Bitar MS, Funaki T, et al. Evidence of oxidative stress in the pathogenesis of fuchs endothelial corneal dystrophy. Am J Pathol. 2010; 177:2278-2289.
8. Buddi R, Lin B, Atilano SR, et al. Evidence of oxidative stress in human corneal diseases. J Histochem Cytochem. 2002; 50:341-351.
9. Joyce NC. Cell cycle status in human corneal endothelium. Exp Eye Res. 2005; 81:629-638.
10. Joyce NC. Proliferative capacity of corneal endothelial cells. Exp Eye Res. 2012; 95:16-23.
11. Mimura T, Joyce NC. Replication competence and senescence in central and peripheral human corneal endothelium. Invest Ophthalmol Vis Sci. 2006; 47:1387-1396.
12. Konomi K, Joyce NC. Age and topographical comparison of telomere lengths in human corneal endothelial cells. Mol Vis. 2007; 13: 1251-1258.
13. Joyce NC, Zhu CC, Harris DL. Relationship among oxidative stress, DNA damage, and proliferative capacity in human corneal endothelium. Invest Ophthalmol Vis Sci. 2009; 50:2116-2122.
14. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4:844-847.
15. Fedor HL, De Marzo AM. Practical methods for tissue microarray construction. Methods Mol Med. 2005; 103:89-101.
16. Simon R. Applications of tissue microarray technology. Methods Mol Biol. 2010; 664:1-16.
17. Bhutto IA, Kim SY, McLeod DS, et al. Localization of collagen XVIII and the endostatin portion of collagen XVIII in aged human control eyes and eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2004; 45:1544-1552.
18. Engelmann K, Böhnke M, Friedl P. Isolation and long-term cultivation of human corneal endothelial cells. Invest Ophthalmol Vis Sci. 1988; 29: 1656-1662.
19. Konomi K, Zhu C, Harris D, et al. Comparison of the proliferative capacity of human corneal endothelial cells from the central and peripheral areas. Invest Ophthalmol Vis Sci. 2005; 46: 4086-4091.
20. Jung YS, Qian Y, Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal. 2010; 22: 1003-1012.
21. Harper JW, Adami GR, Wei N, et al. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993; 75: 805-816.
22. DeGregori J, Leone G, Miron A, et al. Distinct roles for E2F proteins in cell growth control and apoptosis. Proc Natl Acad Sci U S A. 1997; 94: 7245-7250.
23. Sheerin AN, Smith SK, Jennert-Burston K, et al. Characterization of cellular senescence mechanisms in human corneal endothelial cells. Aging Cell. 2012; 11:234-240.
24. Enomoto K, Mimura T, Harris DL, et al. Age differences in cyclindependent kinase inhibitor expression and rb hyperphosphorylation in human corneal endothelial cells. Invest Ophthalmol Vis Sci. 2006; 47: 4330-4340.
25. Azizi B, Ziaei A, Fuchsluger T, et al. p53-regulated increase in oxidativestress-induced apoptosis in Fuchs endothelial corneal dystrophy: a native tissue model. Invest Ophthalmol Vis Sci. 2011; 52:9291-9297.
26. Seluanov A, Gorbunova V, Falcovitz A, et al. Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53. Mol Cell Biol. 2001; 21: 1552-1564.
27. Pei XH, Xiong Y. Biochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues. Oncogene. 2005; 24: 2787-2795.
28. Song Z, Wang Y, Xie L, et al. Expression of senescence-related genes in human corneal endothelial cells. Mol Vis. 2008; 14:161-170.
29. Datta MW, Kahler A, Macias V, et al. A simple inexpensive method for the production of tissue microarrays from needle biopsy specimens: examples with prostate cancer. Appl Immunohistochem Mol Morphol. 2005; 13:96-103.
30. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol. 2008; 26:5630-5637.